Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
Product Unit Size | Cost | Quantity | Stock |
---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
Cas No. | 1258595-14-0 |
---|---|
Purity | ≥99% |
Formula | C29H32F2N3O7P |
Formula Wt. | 603.56 |
IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
Synonym | LHC165 |
Appearance | Pale yellow powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Derivative of aloe-emodin, anthraquinone found ...
SYK/JAK inhibitor
mAChR agonist, selective for M2.
Indole found in cruciferous vegetables; AhR ago...
Cationic lipid polypeptide, mixture of polymyxi...
Pyridopyrimidinone; PI3K and mTOR inhibitor.
Taxane found in Taxus; DNA polymerase inhibitor...
Unlikely to reverse Alzheimer’s
11β-HSD1 inhibitor.
Peptide, used to study cell-surface binding; po...
Used to prevent chromium deficiency and to decr...
Endogenous peptide fragment, immunostimulant; ...
Water-soluble cortisol derivative; glucocortico...
EGFR inhibitor.
β-lactam cephalosporin; penicillin binding pro...
Estradiol metabolite.
Macrocyclic lactone.